July 30, 2025
3 min watch
Key takeaways:
- The businesses will work collectively to develop sustained-release ophthalmic therapies.
- The deal has a possible general worth of greater than $1 billion for Re-Vana.
LONG BEACH, Calif. — Re-Vana Therapeutics is collaborating with Boehringer Ingelheim to develop extended-release therapies for ophthalmic illnesses, in accordance with a press launch.
On the American Society of Retina Specialists annual assembly, Re-Vana CEO Michael O’Rourke instructed Healio that the connection will embrace as much as three target-specific therapeutics from Boehringer Ingelheim to match with Re-Vana’s expertise.
“The objective right here is to have prolonged launch of therapeutics and to cut back the frequency of intravitreal injections, which have been frequent within the business for a few years,” he mentioned.
Re-Vana’s drug supply expertise is designed to slowly launch ophthalmic remedies over the course of 6 to 12 months. O’Rourke mentioned the expertise can also be designed to be administered within the clinic with no surgical procedure required.
The deal consists of funds to Re-Vana with a complete potential worth that exceeds $1 billion along with royalty funds on internet gross sales, in accordance with the discharge.
“Collectively, we need to deal with the boundaries of right this moment’s remedies — aiming to assist folks preserve their sight, with fewer injections,” Nedim Pipic, MD, MSc, world head of psychological well being, eye well being and rising areas at Boehringer Ingelheim, mentioned within the launch. “This partnership is a daring step ahead in our mission to guard imaginative and prescient and ease the burden on sufferers.”
Boehringer Ingelheim will assume duty for medical improvement, regulatory approval and world commercialization of the merchandise, in accordance with the discharge.
“We imagine that that is transformative for Re-Vana,” O’Rourke mentioned. “We expect it’s going to be nice for the business to see an organization like Boehringer Ingelheim actually put quite a lot of funding and dedication into sustained launch.”
Reference:
